We hypothesized a subgroup of CRC tumors may be sensitive to treatment with the combination of MEK and SRC inhibitors and can be selected utilizing gene expression signatures translated into quantitative biomarker scores. The gene discussed is SRC; the disease is colorectal carcinoma.